{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-021758","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.941908+00:00","generated_at":"2026-06-14T03:58:26.826884+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bioventus stockholders approve 2023 Retention Equity Award Plan authorizing 600K shares","bullets":["Stockholders approved 2023 Retention Equity Award Plan, reserving 600,000 shares of Class A common stock for RSUs.","Plan aims to retain critical employees; no awards granted yet; Board approved April 17, 2023, stockholders June 7.","All five Class II director nominees elected with strong shareholder support (82-86% 'for' of votes cast).","Grant Thornton LLP ratified as independent auditor for FY 2023 with 99.9% 'for' votes.","Meeting had 88.78% of outstanding shares represented; about 69.5 million shares voted."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-021758","json":"https://secwatch.observer/filing/0001628280-23-021758.json","markdown":"https://secwatch.observer/filing/0001628280-23-021758.md","text":"https://secwatch.observer/filing/0001628280-23-021758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023021758/0001628280-23-021758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023021758/bvs-20230607.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:58:26.826884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1d75e711307681ae16a635ed712be767ccea5df","claim":"Bioventus Inc. shareholders approved Election of Class II Directors.","evidence_excerpt":"Nominee For Withheld Broker Non-Votes John A. Bartholdson 59,864,373 977,795 8,674,061 Patrick J. Beyer 58,954,599 1,887,569 8,674,061 William A. Hawkins 58,254,590 2,587,578 8,674,061 Mary Kay Ladone 58,552,359 2,289,809 8,674,061 Susan M. Stalnecker 58,586,174 2,255,994 8,674,061","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023021758/0001628280-23-021758-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"ead6cddf7d75f3b88f891745ee8c3627e24675ec","claim":"Bioventus Inc. shareholders approved Approval of the 2023 Plan.","evidence_excerpt":"The stockholders also approved the 2023 Plan described in","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023021758/0001628280-23-021758-index.htm","confidence":0.7,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}